Israel state records י"ג בשבט התשס"ח January 20, 2008

תכשיר צבע המכיל נשא המכיל חלקיקי פירוגלאל, מלחת הברזל (II) וחומצה אורגנית	COLOR COMPRISING AN AGENT CONTAINING PYROGALLOL ENTITIES, A SALT OF IRON (II) AND AN ORGANIC ACID
[54]
	21.07.1997					[22]
	SE	[33]	19.07.1996	[32]	9602818-8	[31]
	US		05.08.1996		60/023222
Int. Cl.8 G01N 033/00, B65D 79/02						[51]
	DIVISION FROM 128069					[62]
			FRESENIUS KABI AB, SWEDEN			[71]
	WO/1998/003866					[87]
סנפורד ט. קולב ושות', שער הגיא 4, מרמורק , ת.ד. 2273, רחובות			SANFORD T.COLB & CO., P.O.B. 2273, REHOVOT 76122			[74]

[57] A method of preparing a transparent flexible container for storing a perishable fluid, which container visually indicates if the perishable fluid has been inadvertently exposed to environmental oxygen which method comprises the subsequent steps of:

(a) assembling together in a controlled atmosphere a transparent, airtight, outer sealing envelope and a primary container made of a partially oxygen permeable material such that a space is defined between the inner container and the outer sealing envelope, said inner container being filled with a perishable fluid;

(b) disposing an oxygen scavenging composition and an oxygen indicator having a reversible color reaction in said space, wherein the oxygen indicator comprises an aqueous solution of an agent containing a pyrrogallol entity, a salt of iron (II), and an acid;

(c) sealing the airtight outer envelope; and

(d) subjecting the container to sterilization.

__________

149757			[21][11]
תכשירי רוקחות המכילים תולדות אמינותיאזול וכמה תרכובות חדשות			PHARMACEUTICAL COMPOSITIONS CONTAINING AMINOTHIAZOLE DERIVATIVES AND SOME NOVEL COMPOUNDS			[54]
	06.12.2000					[22]
	US	[33]	15.12.1999	[32]	09/464511	[31]
Int. Cl.8 A61K 031/426, A61P 029/00, 035/00, 043/00, C07D 277/54, 417/12, 417/14						[51]
			BRISTOL-MYERS SQUIBB PHARMA COMPANY, U.S.A.			[71]
	WO/2001/044217					[87]
וולף, ברגמן וגולר, רחוב קרן היסוד 19ב' , ת.ד. 1352, ירושלים			WOLFF, BREGMAN AND GOLLER, 19B KEREN HAYESOD ST., P.O.B. 1352, JERUSALEM 91013			[74]

[57] A pharmaceutical composition comprising a compound of the formula

and pharmaceutically acceptable salts thereof wherein:

R₁ and R₂ are independently hydrogen, fluorine or alkyl; R₃ is aryl or heteroaryl;

R₄ is alkyl, cycloalkyl, aryl, cycloalkylalkyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl; or CO-alkyl, CO-cycloalkyl, CO-aryl, CO-alkyl-cycloalkyl, CO-alkyl-aryl,

CO-heteroaryl, CO-alkyl-heteroaryl, CO-heterocycloalkyl, CO-alkyl-heterocycloalkyl; or

CONH-alkyl, CONH-cycloalkyl, CONH-aryl, CONH-alkyl-cycloalkyl, CONH-alkyl-aryl, CONH-heteroaryl, CONH-alkyl-heteroaryl, CONH-heterocycloalkyl, CONH-alkyl-heterocycloalkyl; or COO-alkyl, COO-cycloalkyl, COO-aryl, COO-alkyl-cycloalkyl, COO-alkyl-aryl, COO-heteroaryl, COO-alkyl-heteroaryl, COO-heterocycloalkyl, COO-alkyl-heterocycloalkyl; or SO₂-cycloalkyl, SO₂-aryl, SO₂-alkyl-cycloalkyl, SO₂-alkyl-aryl, SO₂-heteroaryl, SO₂-alkyl-heteroaryl, SO₂-heterocycloalkyl, SO₂-alkyl-heterocycloalkyl; or C(NCN)NH-alkyl, C(NCN)NH-cycloalkyl, C(NCN)NH-aryl,

C(NCNNH)-alkyl-cycloalkyl, C(NCN)NH-alkyl-aryl,

C(NCN)NH-heteroaryl, C(NCN)NH-alkyl-heteroaryl,

C(NCN)NH-heterocycloalkyl, C(NCN)NH-alkyl-heterocycloalkyl; or

C(NNO₂) NH-alkyl, C(NNO₂)NH-cycloalkyl, C(NNO₂)NH-aryl, C(NNO₂)NH-alkyl-cycloalkyl, C(NNO₂)NH-alkyl-aryl, C(NNO₂)NH-heteroaryl, C(NNO₂)NH-alkyl-heteroaryl, C(NNO₂)NH-heterocycloalkyl, C(NNO₂)NH-alkyl-heterocycloalkyl; or

C(NH)NH-alkyl, C(NH)NH-cycloalkyl, C(NH)NH-aryl,

C(NH)NH-alkyl-cycloalkyl, C(NH)NH-alkyl-aryl,

C(NH)NH-heteroaryl, C(NH)NH-alkyl-heteroaryl,

C(NH)NH-heterocycloalkyl, C(NH)NH-alkyl-heterocycloalkyl; or

C(NH)NHCO-alkyl, C(NH)NHCO-cycloalkyl, C(NH)NHCO-aryl,

C(NH)NHCO-alkyl-cycloalkyl, C(NH)NHCO-alkyl-aryl,

C(NH)NHCO-heteroaryl, C(NH)NHCO-alkyl-heteroaryl,

C(NH)NHCO-heterocycloalkyl,

C(NH)NHCO-alkyl-heterocycloalkyl; or

C(NOR₆)NH-alkyl, C(NOR₆)NH-cycloalkyl, C(NOR₆)NH-aryl,

C(NOR₆)NH-alkyl-cycloalkyl, C(NOR₆)NH-alkyl-aryl,

C(NOR₆)NH-heteroaryl, C(NOR₆)NH-alkyl-hetaroaryl,

C(NOR₆) NH-heterocycloalkyl, C(NOR₆)NH-alkyl-heterocycloalkyl;

R₅ is hydrogen or alkyl;

R₆ is hydrogen, alkyl, cycloalkyl, aryl, cycloalkylalkyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocyloalkylalkyl;

m is an integer of 0 to 2; and

n is an integer of 1 to 3

in combination with a pharmaceutically acceptable carrier, and a modulator of p53 transactivation formulated as a fixed dose.

__________

149955			[21][11]